Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus A Cohort Study

被引:19
作者
Mok, Chi Chiu [1 ]
Chan, Pak To [1 ]
Ho, Ling Yin [1 ]
Yu, Ka Lung [1 ]
To, Chi Hung [1 ]
机构
[1] Tuen Mun Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
RISK-FACTORS; THROMBOEMBOLISM; DAMAGE; CLASSIFICATION; ANTICOAGULANT; SECONDARY; MORTALITY; CRITERIA; UPDATE; SLE;
D O I
10.1097/MD.0b013e31829cae47
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this work we evaluate the prevalence of the antiphospholipid syndrome (APS) and its impact on survival in Chinese patients with systemic lupus erythematosus (SLE). We studied a prospective cohort of southern Chinese patients who fulfilled >= 4 American College of Rheumatology criteria for SLE. The cumulative rate of survival over time was calculated by the Kaplan-Meier method. APS was defined by the 2006 updated consensus criteria. We evaluated the prevalence and manifestations of APS, and compared the survival of patients with and without APS. We followed 679 patients with SLE (92% women; age of onset, 32.5 +/- 14 yr) for 9.7 +/- 7.3 years. Sixty-eight (10%) patients died and 33 (4.9%) patients were lost to follow-up. Forty-four (6.5%) patients met the criteria for APS, manifested by the following: ischemic stroke (55%), deep venous thrombosis (32%), obstetric morbidity (14%), cardiovascular events (9%), and peripheral vascular disease (9%). Nine (9/44 [20%]) APS patients died, which was more frequent than the non-APS patients (59/635 [9%]; p = 0.02). The cumulative mortality of patients with APS was 4.6% at 5 years, 7.8% at 10 years, and 22.2% at 15 years, which was not significantly higher than that of non-APS patients (5.4% at 5 years, 9.2% at 10 years, and 11.3% at 15 years; p = 0.14). However, if we considered only patients with APS caused by arterial thrombosis, the presence of APS was significantly associated with mortality (hazard ratio, 2.29; 95% confidence interval, 1.13-4.64; p = 0.02). We conclude that the presence of APS increases the mortality risk of Chinese patients with SLE, which is mainly contributed by arterial thrombotic events. Clinical significance: 1) APS is infrequent in southern Chinese patients with SLE compared to white patients. 2) Arterial thrombosis is a more common manifestation of APS than venous thrombosis in Chinese SLE patients. 3) APS related to arterial thrombosis is associated with increased mortality in Chinese patients with SLE.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 23 条
[1]   Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus [J].
Alarcón-Segovia, D ;
Pérez-Ruiz, A ;
Villa, AR .
JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) :157-161
[2]   Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients [J].
Cervera, R. ;
Khamashta, M. A. ;
Shoenfeld, Y. ;
Camps, M. T. ;
Jacobsen, S. ;
Kiss, E. ;
Zeher, M. M. ;
Tincani, A. ;
Kontopoulou-Griva, I. ;
Galeazzi, M. ;
Bellisai, F. ;
Meroni, P. L. ;
Derksen, R. H. W. M. ;
de Groot, P. G. ;
Gromnica-Ihle, E. ;
Baleva, M. ;
Mosca, M. ;
Bombardieri, S. ;
Houssiau, F. ;
Gris, J-C ;
Quere, I. ;
Hachulla, E. ;
Vasconcelos, C. ;
Roch, B. ;
Fernandez-Nebro, A. ;
Piette, J-C ;
Espinosa, G. ;
Bucciarelli, S. ;
Pisoni, C. N. ;
Bertolaccini, M. L. ;
Boffa, M-C ;
Hughes, G. R. V. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (09) :1428-1432
[3]  
DRENKARD C, 1994, J RHEUMATOL, V21, P1067
[4]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[5]   The genetics of venous thromboembolism A meta-analysis involving ∼120,000 cases and 180,000 controls [J].
Gohil, Reya ;
Peck, George ;
Sharma, Pankaj .
THROMBOSIS AND HAEMOSTASIS, 2009, 102 (02) :360-370
[6]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[7]   Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism [J].
Jun, ZJ ;
Ping, T ;
Lei, Y ;
Li, L ;
Ming, SY ;
Jing, W .
CLINICAL AND LABORATORY HAEMATOLOGY, 2006, 28 (02) :111-116
[8]   Antiphospholipid syndrome in systemic lupus erythematosus: Is the whole greater than the sum of its parts? [J].
Laskin, CA ;
Clark, CA ;
Spitzer, KA .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2005, 31 (02) :255-+
[9]   ANTIPHOSPHOLIPID ANTIBODIES - ANTICARDIOLIPIN AND THE LUPUS ANTICOAGULANT IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) AND IN NON-SLE DISORDERS - PREVALENCE AND CLINICAL-SIGNIFICANCE [J].
LOVE, PE ;
SANTORO, SA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (09) :682-698
[10]   Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population [J].
Lu, YH ;
Zhao, YF ;
Liu, GH ;
Wang, XL ;
Liu, ZO ;
Chen, BP ;
Hui, RT .
THROMBOSIS RESEARCH, 2002, 106 (01) :7-12